AgonOx, Inc.
Biotechnology ResearchOregon, United States2-10 Employees
AgonOx, Inc. is a small biotechnology company focused on developing cancer therapies by examining how T cells interact with tumor cells. The company uses bioinformatics alongside in vitro and in vivo experiments to identify and validate new therapeutic approaches. Its research is conducted in laboratories at the Portland Providence Cancer Center, where scientists collaborate with oncologists, surgeons, and immunologists, and it has advanced to two first-in-human clinical trials, the most recent commencing in August 2023. In recent years, AgonOx has focused on leveraging selected tumor-reactive T cells in adoptive cell therapy to treat solid malignancies. The company has engaged in external collaborations to support clinical development, including a May 2023 partnership with Providence Cancer Institute announced through Phio Pharmaceuticals Corp., enabling progression to patient accrual. Based in Portland, Oregon, AgonOx operates within the biotech research sector and maintains a small team dedicated to immuno-oncology research.
1-888-653-2347 
support@leadiq.com 
